Bicara Therapeutics Inc. Common Stock
BCAX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.5B
$23.17
▼ -0.73%
P/E
-7.52
Mkt Cap
$1.5B
52-Wk Range
$10.30–$30.99
52-Week Range
$10.30 - $30.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 88.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary bifunctional antibody platform combining dual-targeting mechanisms
- Biocon Limited backing providing development resources and expertise
- First-mover advantage in EGFR-TGF-beta bifunctional therapy space
Bear Case
1 risk
- Low volatility (beta -0.8).
Growth
Stable outlook
Clinical trial advancement of ficerafusp alfa in multiple solid tumor indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+15.3% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BCAX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 11, 2026
Reported EPS of -$0.82 vs -$0.82 consensus (-0.0% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-0.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
8 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 21, 2026
vs Industry
How BCAX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related